{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:46:58Z","timestamp":1792118818245,"version":"4.4.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02247-8","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T04:13:32Z","timestamp":1782620012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond the JAK2 mutation: The inflammasome, clonal stability, and the thrombotic niche in myeloproliferative neoplasms"],"prefix":"10.1007","volume":"26","author":[{"given":"Amr Ali Mohamed","family":"Abdelgawwad El-Sehrawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutaz Jamal","family":"Al-khreisat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makhfirat","family":"Kibriyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islamova","family":"Dilbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotima","family":"Axmedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jbar Abady","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin Kumar","family":"Tailor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"issue":"1","key":"2247_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01169-6","volume":"14","author":"T Barbui","year":"2024","unstructured":"Barbui T, et al. Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors. Blood Cancer J. 2024;14(1):188. https:\/\/doi.org\/10.1038\/s41408-024-01169-6.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2247_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12657","volume":"6","author":"T Barbui","year":"2022","unstructured":"Barbui T, Carobbio A, De Stefano V. Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Res Pract Thromb Haemost. 2022;6(1):e12657. https:\/\/doi.org\/10.1002\/rth2.12657.","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"2247_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","volume":"8","author":"V De Stefano","year":"2018","unstructured":"De Stefano V, et al. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer J. 2018;8(11):112. https:\/\/doi.org\/10.1038\/s41408-018-0151-y.","journal-title":"Blood Cancer J"},{"issue":"12","key":"2247_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00581-6","volume":"11","author":"P Guglielmelli","year":"2021","unstructured":"Guglielmelli P, et al. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J. 2021;11(12):199. https:\/\/doi.org\/10.1038\/s41408-021-00581-6.","journal-title":"Blood Cancer J"},{"key":"2247_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tru.2021.100081","volume":"5","author":"S Kelliher","year":"2021","unstructured":"Kelliher S, Falanga A. Thrombosis in myeloproliferative neoplasms: a clinical and pathophysiological perspective. Thrombosis Update. 2021;5:100081. https:\/\/doi.org\/10.1016\/j.tru.2021.100081.","journal-title":"Thrombosis Update"},{"key":"2247_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073371","volume":"22","author":"T Bel\u010di\u010d Miki\u010d","year":"2021","unstructured":"Bel\u010di\u010d Miki\u010d T, et al. The contemporary approach to CALR-positive myeloproliferative neoplasms. Int J Mol Sci. 2021;22:3371. https:\/\/doi.org\/10.3390\/ijms22073371.","journal-title":"Int J Mol Sci"},{"key":"2247_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031417","volume":"25","author":"JMP Grenier","year":"2024","unstructured":"Grenier JMP, El Nemer W, De Grandis M. Red blood cell contribution to thrombosis in polycythemia vera and essential thrombocythemia. Int J Mol Sci. 2024;25:1417. https:\/\/doi.org\/10.3390\/ijms25031417.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2247_CR8","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(9):1465\u201387. https:\/\/doi.org\/10.1002\/ajh.27002.","journal-title":"Am J Hematol"},{"issue":"4","key":"2247_CR9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.27216","volume":"99","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(4):697\u2013718. https:\/\/doi.org\/10.1002\/ajh.27216.","journal-title":"Am J Hematol"},{"issue":"26","key":"2247_CR10","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1408617.","journal-title":"N Engl J Med"},{"issue":"2","key":"2247_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1701719.","journal-title":"N Engl J Med"},{"issue":"26","key":"2247_CR12","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477\u201387. https:\/\/doi.org\/10.1056\/NEJMoa1409405.","journal-title":"N Engl J Med"},{"key":"2247_CR13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002943","author":"R Nienhold","year":"2020","unstructured":"Nienhold R, et al. MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. Blood. 2020. https:\/\/doi.org\/10.1182\/blood.2019002943.","journal-title":"Blood"},{"key":"2247_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612700","author":"R Stuckey","year":"2023","unstructured":"Stuckey R, et al. Molecular studies for the early detection of Philadelphia-negative myeloproliferative neoplasms. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241612700.","journal-title":"Int J Mol Sci"},{"key":"2247_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.825611","volume":"9","author":"N Andina","year":"2021","unstructured":"Andina N, Bonadies N, Allam R. Inflammasome activation in myeloid malignancies-friend or foe? Front Cell Dev Biol. 2021;9:825611. https:\/\/doi.org\/10.3389\/fcell.2021.825611.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2247_CR16","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1038\/s41467-022-32927-4","volume":"13","author":"S Rai","year":"2022","unstructured":"Rai S, et al. Inhibition of interleukin-1\u03b2 reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. Nat Commun. 2022;13(1):5346. https:\/\/doi.org\/10.1038\/s41467-022-32927-4.","journal-title":"Nat Commun"},{"issue":"1","key":"2247_CR17","doi-asserted-by":"publisher","first-page":"10591","DOI":"10.1038\/s41467-025-65673-4","volume":"16","author":"RM Koerber","year":"2025","unstructured":"Koerber RM, et al. NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms. Nat Commun. 2025;16(1):10591. https:\/\/doi.org\/10.1038\/s41467-025-65673-4.","journal-title":"Nat Commun"},{"key":"2247_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054860","author":"E Parciante","year":"2023","unstructured":"Parciante E, et al. The role of NLRP3, a star of excellence in myeloproliferative neoplasms. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24054860.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2247_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41375-025-02836-8","volume":"40","author":"A Guy","year":"2026","unstructured":"Guy A, et al. Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms. Leukemia. 2026;40(2):360\u201372. https:\/\/doi.org\/10.1038\/s41375-025-02836-8.","journal-title":"Leukemia"},{"issue":"2","key":"2247_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377(2):111\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1701719.","journal-title":"N Engl J Med"},{"key":"2247_CR21","doi-asserted-by":"crossref","unstructured":"Waisman DM, Bharadwaj AG, Okura GC. Thrombo-Hemorrhagic Complications in Myeloproliferative Neoplasms: Etiology, Pathobiology, and Therapeutic Considerations, in Fibrinolysis - Past, Present and Future, D.M. Waisman and A.G. Bharadwaj, Editors. 2024, IntechOpen: London.","DOI":"10.5772\/intechopen.115533"},{"issue":"15","key":"2247_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1182\/blood.2023022260","volume":"143","author":"W Liu","year":"2024","unstructured":"Liu W, et al. Jak2 V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talk. Blood. 2024;143(15):1539\u201350. https:\/\/doi.org\/10.1182\/blood.2023022260.","journal-title":"Blood"},{"issue":"6327","key":"2247_CR23","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","volume":"355","author":"JJ Fuster","year":"2017","unstructured":"Fuster JJ, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842\u20137. https:\/\/doi.org\/10.1126\/science.aag1381.","journal-title":"Science"},{"issue":"20","key":"2247_CR24","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood.2024024187","volume":"144","author":"RL Zon","year":"2024","unstructured":"Zon RL, et al. JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism. Blood. 2024;144(20):2149\u201354. https:\/\/doi.org\/10.1182\/blood.2024024187.","journal-title":"Blood"},{"issue":"1","key":"2247_CR25","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1038\/s41467-022-32986-7","volume":"13","author":"DW Brown","year":"2022","unstructured":"Brown DW, et al. Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis. Nat Commun. 2022;13(1):5284. https:\/\/doi.org\/10.1038\/s41467-022-32986-7.","journal-title":"Nat Commun"},{"issue":"4","key":"2247_CR26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/ng.334","volume":"41","author":"AV Jones","year":"2009","unstructured":"Jones AV, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446\u20139. https:\/\/doi.org\/10.1038\/ng.334.","journal-title":"Nat Genet"},{"issue":"6","key":"2247_CR27","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/leu.2014.48","volume":"28","author":"A Oddsson","year":"2014","unstructured":"Oddsson A, et al. The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia. 2014;28(6):1371\u20134. https:\/\/doi.org\/10.1038\/leu.2014.48.","journal-title":"Leukemia"},{"issue":"5","key":"2247_CR28","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41375-023-01886-0","volume":"37","author":"N Maslah","year":"2023","unstructured":"Maslah N, et al. Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape. Leukemia. 2023;37(5):957\u201363. https:\/\/doi.org\/10.1038\/s41375-023-01886-0.","journal-title":"Leukemia"},{"issue":"8","key":"2247_CR29","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.exphem.2015.11.005","volume":"44","author":"L Wang","year":"2016","unstructured":"Wang L, Wheeler DA, Prchal JT. Acquired uniparental disomy of chromosome 9p in hematologic malignancies. Exp Hematol. 2016;44(8):644\u201352. https:\/\/doi.org\/10.1016\/j.exphem.2015.11.005.","journal-title":"Exp Hematol"},{"key":"2247_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/606819","volume":"2015","author":"AG Fleischman","year":"2015","unstructured":"Fleischman AG. Inflammation as a driver of clonal evolution in myeloproliferative neoplasm. Mediators Inflamm. 2015;2015:606819. https:\/\/doi.org\/10.1155\/2015\/606819.","journal-title":"Mediators Inflamm"},{"issue":"24","key":"2247_CR31","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","volume":"118","author":"AG Fleischman","year":"2011","unstructured":"Fleischman AG, et al. TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118(24):6392\u20138. https:\/\/doi.org\/10.1182\/blood-2011-04-348144.","journal-title":"Blood"},{"issue":"5","key":"2247_CR32","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1182\/bloodadvances.2023011338","volume":"8","author":"S Rai","year":"2024","unstructured":"Rai S, et al. IL-1\u03b2 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells. Blood Adv. 2024;8(5):1234\u201349. https:\/\/doi.org\/10.1182\/bloodadvances.2023011338.","journal-title":"Blood Adv"},{"issue":"2","key":"2247_CR33","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/leu.2017.233","volume":"32","author":"H Zhan","year":"2018","unstructured":"Zhan H, et al. The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms. Leukemia. 2018;32(2):462\u20139. https:\/\/doi.org\/10.1038\/leu.2017.233.","journal-title":"Leukemia"},{"key":"2247_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101001","volume":"58","author":"Z Xie","year":"2023","unstructured":"Xie Z, Zeidan AM. CHIPing away the progression potential of CHIP: a new reality in the making. Blood Rev. 2023;58:101001. https:\/\/doi.org\/10.1016\/j.blre.2022.101001.","journal-title":"Blood Rev"},{"issue":"1","key":"2247_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01562-5","volume":"17","author":"TR Haage","year":"2024","unstructured":"Haage TR, et al. Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia. J Hematol Oncol. 2024;17(1):43. https:\/\/doi.org\/10.1186\/s13045-024-01562-5.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2247_CR36","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1161\/ATVBAHA.120.314760","volume":"40","author":"S Matsuura","year":"2020","unstructured":"Matsuura S, et al. Platelet dysfunction and thrombosis in JAK2V617F-mutated primary myelofibrotic mice. Arterioscler Thromb Vasc Biol. 2020;40(10):e262\u201372. https:\/\/doi.org\/10.1161\/ATVBAHA.120.314760.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2247_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13102543","author":"A Dr\u0103gan","year":"2025","unstructured":"Dr\u0103gan A, et al. Clinical and molecular insights of arterial and venous thrombosis in myeloproliferative diseases-case-based narrative review. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13102543.","journal-title":"Biomedicines"},{"issue":"3","key":"2247_CR38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4274\/tjh.galenos.2024.2024.0161","volume":"41","author":"R Diz-K\u00fc\u00e7\u00fckkaya","year":"2024","unstructured":"Diz-K\u00fc\u00e7\u00fckkaya R, et al. JAK2V617F mutation in endothelial cells of patients with atherosclerotic carotid disease. Turk J Haematol. 2024;41(3):167\u201374. https:\/\/doi.org\/10.4274\/tjh.galenos.2024.2024.0161.","journal-title":"Turk J Haematol"},{"key":"2247_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2025.109407","volume":"253","author":"SF Toprak","year":"2025","unstructured":"Toprak SF, et al. JAK2V617F-positive extracellular genomic materials drive endothelial inflammation and thrombosis in myeloproliferative neoplasms. Thromb Res. 2025;253:109407. https:\/\/doi.org\/10.1016\/j.thromres.2025.109407.","journal-title":"Thromb Res"},{"issue":"1","key":"2247_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe M, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;33(1):29-43.e7. https:\/\/doi.org\/10.1016\/j.ccell.2017.11.009.","journal-title":"Cancer Cell"},{"issue":"22","key":"2247_CR41","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","volume":"123","author":"R Rampal","year":"2014","unstructured":"Rampal R, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123(22):e123-33. https:\/\/doi.org\/10.1182\/blood-2014-02-554634.","journal-title":"Blood"},{"key":"2247_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.111122","volume":"399","author":"L Zhao","year":"2024","unstructured":"Zhao L, et al. Cadmium activates the innate immune system through the AIM2 inflammasome. Chem Biol Interact. 2024;399:111122. https:\/\/doi.org\/10.1016\/j.cbi.2024.111122.","journal-title":"Chem Biol Interact"},{"issue":"5","key":"2247_CR43","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12012-020-09576-4","volume":"20","author":"S Wei","year":"2020","unstructured":"Wei S, et al. Involvement of ROS\/NLRP3 inflammasome signaling pathway in doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol. 2020;20(5):507\u201319. https:\/\/doi.org\/10.1007\/s12012-020-09576-4.","journal-title":"Cardiovasc Toxicol"},{"key":"2247_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110525","volume":"130","author":"A Xu","year":"2020","unstructured":"Xu A, et al. NF-\u03baB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity. Biomed Pharmacother. 2020;130:110525. https:\/\/doi.org\/10.1016\/j.biopha.2020.110525.","journal-title":"Biomed Pharmacother"},{"issue":"18","key":"2247_CR45","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1182\/bloodadvances.2020004061","volume":"5","author":"S Schmidt","year":"2021","unstructured":"Schmidt S, et al. Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events. Blood Adv. 2021;5(18):3515\u201327. https:\/\/doi.org\/10.1182\/bloodadvances.2020004061.","journal-title":"Blood Adv"},{"issue":"1","key":"2247_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01933-x","volume":"9","author":"H Wang","year":"2024","unstructured":"Wang H, et al. Neutrophil extracellular traps in homeostasis and disease. Signal Transduct Target Ther. 2024;9(1):235. https:\/\/doi.org\/10.1038\/s41392-024-01933-x.","journal-title":"Signal Transduct Target Ther"},{"key":"2247_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan8292","author":"O Wolach","year":"2018","unstructured":"Wolach O, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018. https:\/\/doi.org\/10.1126\/scitranslmed.aan8292.","journal-title":"Sci Transl Med"},{"issue":"4","key":"2247_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41408-021-00470-y","volume":"11","author":"P Guglielmelli","year":"2021","unstructured":"Guglielmelli P, et al. Mutations and thrombosis in essential thrombocythemia. Blood Cancer J. 2021;11(4):77. https:\/\/doi.org\/10.1038\/s41408-021-00470-y.","journal-title":"Blood Cancer J"},{"key":"2247_CR49","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6268514","author":"MH Bao","year":"2020","unstructured":"Bao MH, et al. A novel putative role of TNK1 in atherosclerotic inflammation implicating the Tyk2\/STAT1 pathway. Mediators Inflamm. 2020. https:\/\/doi.org\/10.1155\/2020\/6268514.","journal-title":"Mediators Inflamm"},{"key":"2247_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2024.109092","volume":"241","author":"AD Peshkova","year":"2024","unstructured":"Peshkova AD, et al. The differential formation and composition of leukocyte-platelet aggregates induced by various cellular stimulants. Thromb Res. 2024;241:109092. https:\/\/doi.org\/10.1016\/j.thromres.2024.109092.","journal-title":"Thromb Res"},{"issue":"2","key":"2247_CR51","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/ijlh.13754","volume":"44","author":"D \u0160efer","year":"2022","unstructured":"\u0160efer D, et al. Correlation between leukocyte-platelet aggregates and thrombosis in myeloproliferative neoplasms. Int J Lab Hematol. 2022;44(2):302\u201312. https:\/\/doi.org\/10.1111\/ijlh.13754.","journal-title":"Int J Lab Hematol"},{"key":"2247_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/0471142956.cy0615s24","author":"M Barnard","year":"2003","unstructured":"Barnard M, et al. Whole blood analysis of leukocyte-platelet aggregates. Curr Protoc Cytom. 2003. https:\/\/doi.org\/10.1002\/0471142956.cy0615s24.","journal-title":"Curr Protoc Cytom"},{"issue":"1","key":"2247_CR53","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s12951-022-01584-6","volume":"20","author":"X Guo","year":"2022","unstructured":"Guo X, Sui R, Piao H. Tumor-derived small extracellular vesicles: potential roles and mechanism in glioma. J Nanobiotechnol. 2022;20(1):383. https:\/\/doi.org\/10.1186\/s12951-022-01584-6.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"2247_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4274\/tjh.galenos.2024.2023.0430","volume":"41","author":"Z Narl\u0131 \u00d6zdemir","year":"2024","unstructured":"Narl\u0131 \u00d6zdemir Z, et al. Impact of CALR and JAK2V617F mutations on clinical course and disease outcomes in essential thrombocythemia: a multicenter retrospective study in Turkish patients. Turk J Haematol. 2024;41(1):26\u201336. https:\/\/doi.org\/10.4274\/tjh.galenos.2024.2023.0430.","journal-title":"Turk J Haematol"},{"issue":"5","key":"2247_CR55","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/bjh.13539","volume":"172","author":"JM Torregrosa","year":"2016","unstructured":"Torregrosa JM, et al. Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation. Br J Haematol. 2016;172(5):813\u20135. https:\/\/doi.org\/10.1111\/bjh.13539.","journal-title":"Br J Haematol"},{"issue":"0","key":"2247_CR56","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.5045\/br.2023.2023038","volume":"58","author":"J Hong","year":"2023","unstructured":"Hong J. Prognostication in myeloproliferative neoplasms, including mutational abnormalities. Blood Res. 2023;58(0):S37\u201345. https:\/\/doi.org\/10.5045\/br.2023.2023038.","journal-title":"Blood Res"},{"key":"2247_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0159-0","author":"I Triviai","year":"2019","unstructured":"Triviai I, et al. ASXL1\/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF. Leukemia. 2019. https:\/\/doi.org\/10.1038\/s41375-018-0159-0.","journal-title":"Leukemia"},{"issue":"3","key":"2247_CR58","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12185-025-04038-5","volume":"122","author":"N Sato","year":"2025","unstructured":"Sato N, Goyama S, Kitamura T. ASXL1 mutation-related clonal hematopoiesis and age-related diseases: clinical evidence and molecular insights. Int J Hematol. 2025;122(3):327\u201340. https:\/\/doi.org\/10.1007\/s12185-025-04038-5.","journal-title":"Int J Hematol"},{"issue":"1","key":"2247_CR59","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s12964-024-01877-3","volume":"22","author":"E Peroni","year":"2024","unstructured":"Peroni E, et al. Spatial-transcriptomic profiling: a new lens for understanding myelofibrosis pathophysiology. Cell Commun Signal. 2024;22(1):510. https:\/\/doi.org\/10.1186\/s12964-024-01877-3.","journal-title":"Cell Commun Signal"},{"issue":"S3","key":"2247_CR60","doi-asserted-by":"publisher","first-page":"e8815033","DOI":"10.1097\/01.HS9.0000975676.88150.33","volume":"7","author":"O Altunok","year":"2023","unstructured":"Altunok O, Serin I, Yokus O. PB2234: EFFECT OF HYDROXYUREA ON INFLAMMATORY MARKERS IN PATIENTS WITH BCR-ABL NEGATIVE MYELOPROLIFERATIVE DISEASES. HemaSphere. 2023;7(S3):e8815033.","journal-title":"HemaSphere"},{"issue":"4","key":"2247_CR61","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3324\/haematol.2023.283958","volume":"110","author":"F Pasquier","year":"2025","unstructured":"Pasquier F, et al. New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-\u03b1 alter the natural history of the disease? Haematologica. 2025;110(4):850\u201362. https:\/\/doi.org\/10.3324\/haematol.2023.283958.","journal-title":"Haematologica"},{"issue":"9","key":"2247_CR62","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557.","journal-title":"N Engl J Med"},{"issue":"19","key":"2247_CR63","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1200\/jco.22.01935","volume":"41","author":"CN Harrison","year":"2023","unstructured":"Harrison CN, et al. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol. 2023;41(19):3534\u201344. https:\/\/doi.org\/10.1200\/jco.22.01935.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2247_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70000","volume":"6","author":"R Dunn","year":"2025","unstructured":"Dunn R, et al. Treatment of myeloproliferative neoplasms with janus kinase inhibitors: a meta-analysis of cardiovascular safety. EJHaem. 2025;6(1):e70000. https:\/\/doi.org\/10.1002\/jha2.70000.","journal-title":"EJHaem"},{"issue":"3","key":"2247_CR65","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/s2352-3026(19)30207-8","volume":"7","author":"JJ Kiladjian","year":"2020","unstructured":"Kiladjian JJ, et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020;7(3):e226\u201337. https:\/\/doi.org\/10.1016\/s2352-3026(19)30207-8.","journal-title":"Lancet Haematol"},{"key":"2247_CR66","doi-asserted-by":"publisher","first-page":"82","DOI":"10.12688\/f1000research.13167.1","volume":"7","author":"W Vainchenker","year":"2018","unstructured":"Vainchenker W, et al. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Res. 2018;7:82. https:\/\/doi.org\/10.12688\/f1000research.13167.1.","journal-title":"F1000Res"},{"issue":"4","key":"2247_CR67","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1038\/bcj.2013.6","volume":"3","author":"L Ma","year":"2013","unstructured":"Ma L, et al. Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J. 2013;3(4):e109. https:\/\/doi.org\/10.1038\/bcj.2013.6.","journal-title":"Blood Cancer J"},{"issue":"5","key":"2247_CR68","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/2643-3230.Bcd-22-0189","volume":"4","author":"PC Nair","year":"2023","unstructured":"Nair PC, et al. Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. Blood Cancer Discov. 2023;4(5):352\u201364. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-22-0189.","journal-title":"Blood Cancer Discov"},{"key":"2247_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2026.118642","volume":"307","author":"Y Yang","year":"2026","unstructured":"Yang Y, et al. Rational design of dual PB2\/JAK2 inhibitors achieving balanced antiviral and host-directed immunomodulatory effects. Eur J Med Chem. 2026;307:118642. https:\/\/doi.org\/10.1016\/j.ejmech.2026.118642.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"2247_CR70","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll RC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248\u201355. https:\/\/doi.org\/10.1038\/nm.3806.","journal-title":"Nat Med"},{"key":"2247_CR71","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2023.5238","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (review). Int J Mol Med. 2023. https:\/\/doi.org\/10.3892\/ijmm.2023.5238.","journal-title":"Int J Mol Med"},{"issue":"5","key":"2247_CR72","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","volume":"376","author":"I Ataga Kenneth","year":"2017","unstructured":"Ataga Kenneth I, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1611770.","journal-title":"N Engl J Med"},{"key":"2247_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010011","author":"A Liu","year":"2022","unstructured":"Liu A, Naymagon L, Tremblay D. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment considerations and unmet needs. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers15010011.","journal-title":"Cancers (Basel)"},{"key":"2247_CR74","unstructured":"A Phase 2 Study of Canakinumab in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 122]. 2022."},{"issue":"12","key":"2247_CR75","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914.","journal-title":"N Engl J Med"},{"issue":"5","key":"2247_CR76","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","volume":"7","author":"EC Svensson","year":"2022","unstructured":"Svensson EC, et al. TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. JAMA Cardiol. 2022;7(5):521\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2022.0386.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"2247_CR77","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1007\/s00259-019-04603-1","volume":"47","author":"PF H\u00f8ilund-Carlsen","year":"2020","unstructured":"H\u00f8ilund-Carlsen PF, et al. Atherosclerosis imaging with (18)F-sodium fluoride PET: state-of-the-art review. Eur J Nucl Med Mol Imaging. 2020;47(6):1538\u201351. https:\/\/doi.org\/10.1007\/s00259-019-04603-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2247_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.511391","volume":"11","author":"M Mayer","year":"2020","unstructured":"Mayer M, et al. Imaging atherosclerosis by PET, with emphasis on the role of FDG and NaF as potential biomarkers for this disorder. Front Physiol. 2020;11:511391. https:\/\/doi.org\/10.3389\/fphys.2020.511391.","journal-title":"Front Physiol"},{"key":"2247_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11122234","author":"WY Raynor","year":"2021","unstructured":"Raynor WY, et al. PET-based imaging with (18)F-FDG and (18)F-NaF to assess inflammation and microcalcification in atherosclerosis and other vascular and thrombotic disorders. Diagnostics (Basel). 2021. https:\/\/doi.org\/10.3390\/diagnostics11122234.","journal-title":"Diagnostics (Basel)"},{"key":"2247_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2023.101589","volume":"37","author":"A Liang","year":"2024","unstructured":"Liang A, et al. Advancements and applications of single-cell multi-omics techniques in cancer research: unveiling heterogeneity and paving the way for precision therapeutics. Biochem Biophys Rep. 2024;37:101589. https:\/\/doi.org\/10.1016\/j.bbrep.2023.101589.","journal-title":"Biochem Biophys Rep"},{"issue":"Supplement 1","key":"2247_CR81","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.1182\/blood-2024-210924","volume":"144","author":"J Castorena","year":"2024","unstructured":"Castorena J, et al. Spatial transcriptomic profiling of bone marrow vascular niches unveils an endothelial stress signature in myeloproliferative neoplasms. Blood. 2024;144(Supplement 1):4516\u20134516. https:\/\/doi.org\/10.1182\/blood-2024-210924.","journal-title":"Blood"},{"key":"2247_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.914347","volume":"13","author":"H Yang","year":"2022","unstructured":"Yang H, et al. Synergistic effect of VEGF and SDF-1\u03b1 in endothelial progenitor cells and vascular smooth muscle cells. Front Pharmacol. 2022;13:914347. https:\/\/doi.org\/10.3389\/fphar.2022.914347.","journal-title":"Front Pharmacol"},{"key":"2247_CR83","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.exphem.2017.11.002","volume":"59","author":"SO Abegunde","year":"2018","unstructured":"Abegunde SO, et al. An inflammatory environment containing TNF\u03b1 favors Tet2-mutant clonal hematopoiesis. Exp Hematol. 2018;59:60\u20135. https:\/\/doi.org\/10.1016\/j.exphem.2017.11.002.","journal-title":"Exp Hematol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02247-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02247-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02247-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:03:38Z","timestamp":1782698618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02247-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2247"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02247-8","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors used generative-AI \/ language-assistance tools (InstaText, Wordvice and DeepL) only for structural editing and language polishing. These tools were not used to generate scientific content, interpret results, or create citations. All factual claims, data statements, and references cited in this manuscript were checked and verified manually by the authors against the original source papers prior to submission; no citations were fabricated or created by AI. The authors accept full responsibility for the accuracy and integrity of the content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI statement"}},{"value":"This paper is submitted with the agreement of all its co-authors and the author list has been approved by all authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Agreement"}}],"article-number":"241"}}